---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-201735"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T15:44:54.993198+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Teva elects Prof. Varda Shalev to Board effective Sep 1, 2023

## Summary
- Prof. Varda Shalev elected as independent director, effective Sep 1, 2023, until 2024 annual meeting.
- Shalev is a healthcare executive, managing partner at Team8 Health VC, and professor at Tel Aviv University.
- No arrangements or material interests with other parties; compensation same as other non-executive directors.
- No family relationships with any director or executive officer of Teva.

## SEC filing metadata
- accession: 0001193125-23-201735
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312523201735/0001193125-23-201735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312523201735/d512916d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-201735
- JSON: https://secwatch.observer/filing/0001193125-23-201735.json
- Plain text: https://secwatch.observer/filing/0001193125-23-201735.txt

## Key facts
- Executive change
  Prof. Varda Shalev was elected as member of the Board at TEVA PHARMACEUTICAL INDUSTRIES LTD.
  - Action: elected
  - Role: member of the Board
  source text: On August 1, 2023, at a meeting of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”), the Board elected Prof. Varda Shalev to serve as a member of the Board, effective September 1, 2023, until Teva’s 2024 annual meeting of shareholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/818686/000119312523201735/0001193125-23-201735-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.